CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
输注前疾病负荷对 anti-CD19 CAR-T 细胞治疗后儿童复发/难治性 B 细胞淋巴细胞白血病结局的影响
英文原题：Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.
查看英文原题
Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向 CD19 的嵌合抗原受体（CAR）T 细胞疗法治疗复发/难治性（R/R）B 急性淋巴细胞白血病（B-ALL）儿童患者显示出高疗效，但输注后复发仍是挑战。
本研究评估了本中心接受抗 CD19 CAR-T 细胞治疗的 116 例 R/R B-ALL 儿童。所有患者均纳入应答分析，并评估其生存和毒性。完全缓解（CR）率为 98.3%，90.5% 的患者在第 28 天（d28）达到微小残留病（MRD）阴性 CR。中位随访时间为 47.9 个月；总生存率（OS）为 69.3% ± 4.5%，无事件生存率（EFS）为 59.0% ± 4.6%。输注前 MRD ≥1% 的患者，4 年 OS（p = 0.006）和 EFS（p = 0.027）均低于输注前 MRD <1% 的患者。3 级细胞因子释放综合征（CRS）和神经毒性发生率分别为 21.6% 和 5.0%。
因此，输注前疾病负荷可预测儿童 R/R B-ALL 患者接受抗 CD19 CAR-T 细胞治疗后的长期结局。
展开英文摘要原文
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies have demonstrated high efficacy in pediatric patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Despite this success, the challenge of post-infusion relapse persists. In our study, we evaluate 116 children with R/R B-ALL who received anti-CD19 CAR T-cell therapy at our center. All patients were included in the response analysis and assessed for survival and toxicity. The CR rate was 98. 3%, with 90.
5% achieving minimal residual disease negative (MRD) - CR by day 28 (d28). The overall survival (OS) and event-free survival (EFS) were 69. 3% 4. 5% and 59. 0% 4. 6%, respectively, with a median follow-up duration of 47. 9 months. The patients with pre-infusion MRD 1% was associated with lower 4-year OS ( p = 0. 006) and EFS ( p = 0. 027) comparing to those with MRD < 1%. The incidences of grade 3 cytokine release syndrome (CRS) and neurotoxicity were21. 6 and 5. 0%, respectively.
Therefore, pre-infusion disease burden is a predictor of long-term outcome following anti-CD19 CAR T-cell therapy for pediatric R/R B-ALL.
论文信息
- 作者
- Shang Q、Wang Y、Lu A、Jia Y、Zuo Y、Zeng H、Zhang L
- 单位
- Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.China
- 期刊
- Leukemia & lymphoma2025 Jan
- 原文标识
- PubMed 39378242 · DOI 10.1080/10428194.2024.2406958